Leijenaar, Ralph T. H.
Walsh, Sean
Akshayaa Vaidyanathan,
Aliboni, Lorenzo
Sanchez, Victoria Lopez
Leech, Michelle
Joyce, Ronan
Gillham, Charles
Kridelka, Frédéric
Hustinx, Roland
Danthine, Denis
Occhipinti, Mariaelena
Vos, Wim
Guiot, Julien
Lambin, Philippe
Lovinfosse, Pierre
Article History
Received: 13 September 2022
Accepted: 25 April 2023
First Online: 3 May 2023
Competing interests
: R. T.H. L. has shares in the company Radiomics and is co-inventor of an issued patent with royalties on radiomics (PCT/NL2014/050728) licensed to Radiomics. R. T.H. L. is a former employee of Radiomics. S. W. reports personal fees from Radiomics, outside the submitted work A.V., L. A., V. S. L. are salaried employees of Radiomics. M. O. reports personal fees from Radiomics, outside the submitted work. J. G. reports, outside the submitted work, research agreements from Radiomics. He is in the permanent SAB of Radiomics for the SALMON trial without any specific consultancy fee for this work. He is co-inventor of one issued patent on radiomics licensed to Radiomics. P.L. reports, within and outside the submitted work, the following disclosures: grants/sponsored research agreements from Radiomics SA, Convert Pharmaceuticals and LivingMed Biotech. He received a presenter fee (in cash or in kind) and/or reimbursement of travel costs/consultancy fee (in cash or in kind) from Radiomics SA, BHV. PL has minority shares in the companies Radiomics SA, Convert pharmaceuticals, Comunicare, LivingMed Biotech and Bactam. PL is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248 and PCT/NL2014/050728), licensed to Radiomics SA; one issued patent on mtDNA (PCT/EP2014/059089), licensed to ptTheragnostic/DNAmito; one non-issued patent on LSRT (PCT/ P126537PC00), licensed to Varian; three non-patented inventions (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures and two non-issued, non-licensed patents on Deep Learning-Radiomics (N2024482, N2024889). grants/sponsored research agreements from Radiomics, ptTheragnostic/DNAmito, Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/consultancy fee and/or in kind manpower contribution from radiomics SA, BHV, Merck, Varian, Elekta, ptTheragnostic, BMS and Convert pharmaceuticals. Dr Lambin has minority shares in the company Radiomics SA, Convert pharmaceuticals, Comunicare Solutions and LivingMed Biotech, he is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Radiomics SA and one issued patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, one non issued patent on LSRT (PCT/ P126537PC00) licensed to Varian Medical, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures and three non-issues, non licensed patents on Deep & handcrafted Radiomics (US P125078US00, PCT/NL/2020/050794, n° N2028271). W. V. have shares in the company Radiomics. The rest of co-authors have no competing interest to disclose.